CD8A and lung carcinoma: Our study demonstrates that LMB-100/αPD-1 antibody combination enhances CD8 T cells mediated anti-tumor efficacy in hMSLN expressing syngeneic lung cancer mouse model and humanized mesothelioma mouse model.